The concept of using mRNA to produce its own medicine in situ in the body makes it an ideal
drug candidate, holding great potential to revolutionize the way we approach medicine. The …

Gene therapy is an emerging and promising strategy in cancer therapy where small
interfering RNA (siRNA) system has been deployed for down-regulation of targeted gene …

Polysaccharides are biopolymers distinguished by their complex secondary structures
executing various roles in microorganisms, plants, and animals. They are made up of long …

Five small interfering RNA (siRNA)-based therapeutics have been approved by the Food
and Drug Administration (FDA), namely patisiran, givosiran, lumasiran, inclisiran, and …

Synthetic nanoparticles (NPs) are non-viral equivalents of viral gene delivery systems that
are actively explored to deliver a spectrum of nucleic acids for diverse range of therapies …

Doxorubicin (DOX) is one of the most commonly used drugs in liver cancer. Unfortunately,
the traditional chemotherapy with DOX presents many limitations, such as a systematic …

Excessive transforming growth factor β1 (TGF-β1) secreted by activated hepatic stellate cells
(aHSCs) aggravates liver fibrosis via over-activation of TGF-β1-mediated signaling …

Liver fibrosis is the deposition of extracellular matrix (ECM) in the liver caused by persistent
chronic injury, which can lead to more serious diseases such as cirrhosis or cancer …

Alzheimer's disease (AD) is the most common type of dementia. Increasing evidence is
showing the important role of mitochondrial dysfunction in AD. Mitochondria based oxidative …

Truncated transforming growth factor β receptor type II (tTβRII) is a promising anti-liver
fibrotic candidate because it serves as a trap for binding excessive TGF-β1 by means of …